|
Glaukos Corporation (GKOS) DCF Valoración
US | Healthcare | Medical - Devices | NYSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Glaukos Corporation (GKOS) Bundle
¡Simplifique la valoración de Glaukos Corporation (GKOS) con esta calculadora DCF personalizable! Con las finanzas de Real Glaukos Corporation (GKOS) y las entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Glaukos Corporation (GKOS) en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 237.0 | 225.0 | 294.0 | 282.9 | 314.7 | 340.7 | 368.9 | 399.5 | 432.5 | 468.3 |
| Revenue Growth, % | 0 | -5.07 | 30.7 | -3.79 | 11.26 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 |
| EBITDA | -37.6 | -83.6 | -1.5 | -48.8 | -82.1 | -66.0 | -71.5 | -77.4 | -83.8 | -90.7 |
| EBITDA, % | -15.87 | -37.16 | -0.50134 | -17.24 | -26.09 | -19.37 | -19.37 | -19.37 | -19.37 | -19.37 |
| Depreciation | 9.9 | 34.6 | 34.4 | 35.9 | 38.0 | 38.2 | 41.3 | 44.8 | 48.5 | 52.5 |
| Depreciation, % | 4.16 | 15.39 | 11.71 | 12.71 | 12.07 | 11.21 | 11.21 | 11.21 | 11.21 | 11.21 |
| EBIT | -47.5 | -118.2 | -35.9 | -84.7 | -120.1 | -104.2 | -112.8 | -122.1 | -132.2 | -143.2 |
| EBIT, % | -20.03 | -52.54 | -12.21 | -29.95 | -38.16 | -30.58 | -30.58 | -30.58 | -30.58 | -30.58 |
| Total Cash | 174.0 | 404.4 | 414.1 | 352.7 | 295.4 | 318.5 | 344.8 | 373.3 | 404.2 | 437.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 38.4 | 36.1 | 33.4 | 36.1 | 39.9 | 47.0 | 50.9 | 55.1 | 59.7 | 64.6 |
| Account Receivables, % | 16.21 | 16.03 | 11.37 | 12.75 | 12.66 | 13.81 | 13.81 | 13.81 | 13.81 | 13.81 |
| Inventories | 42.6 | 15.8 | 23.0 | 37.8 | 42.0 | 40.6 | 43.9 | 47.6 | 51.5 | 55.8 |
| Inventories, % | 17.97 | 7.03 | 7.83 | 13.38 | 13.34 | 11.91 | 11.91 | 11.91 | 11.91 | 11.91 |
| Accounts Payable | 5.8 | 4.4 | 7.3 | 14.4 | 13.4 | 11.1 | 12.0 | 13.0 | 14.0 | 15.2 |
| Accounts Payable, % | 2.44 | 1.94 | 2.49 | 5.09 | 4.27 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
| Capital Expenditure | -4.7 | -6.9 | -47.8 | -30.3 | -20.2 | -26.2 | -28.4 | -30.7 | -33.3 | -36.0 |
| Capital Expenditure, % | -1.99 | -3.08 | -16.25 | -10.7 | -6.43 | -7.69 | -7.69 | -7.69 | -7.69 | -7.69 |
| Tax Rate, % | -0.69844 | -0.69844 | -0.69844 | -0.69844 | -0.69844 | -0.69844 | -0.69844 | -0.69844 | -0.69844 | -0.69844 |
| EBITAT | 14.6 | -107.5 | -36.1 | -85.4 | -120.9 | -81.5 | -88.2 | -95.5 | -103.4 | -112.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -55.4 | -52.1 | -51.1 | -90.1 | -112.1 | -77.7 | -81.6 | -88.3 | -95.6 | -103.5 |
| WACC, % | 8.84 | 9.04 | 9.06 | 9.06 | 9.06 | 9.01 | 9.01 | 9.01 | 9.01 | 9.01 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -343.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -106 | |||||||||
| Terminal Value | -1,506 | |||||||||
| Present Terminal Value | -978 | |||||||||
| Enterprise Value | -1,321 | |||||||||
| Net Debt | 290 | |||||||||
| Equity Value | -1,612 | |||||||||
| Diluted Shares Outstanding, MM | 48 | |||||||||
| Equity Value Per Share | -33.28 |
What You Will Get
- Real GKOS Financial Data: Pre-filled with Glaukos Corporation’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Glaukos Corporation’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Customizable Financial Inputs: Adjust essential parameters such as revenue projections, EBITDA margins, and capital investments.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and other financial metrics in real-time.
- High-Precision Results: Leverages Glaukos Corporation's (GKOS) real financial data for accurate valuation insights.
- Effortless Scenario Testing: Easily explore various assumptions and analyze the resulting impacts.
- Efficiency Booster: Streamline the valuation process by avoiding the complexities of building models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Glaukos Corporation’s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions regarding Glaukos Corporation (GKOS).
Why Choose This Calculator for Glaukos Corporation (GKOS)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and healthcare consultants.
- Accurate Data: Glaukos Corporation's historical and projected financials are preloaded for precision.
- Forecast Scenarios: Easily simulate various projections and assumptions for informed decision-making.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a seamless experience throughout the process.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and accurate valuation models for Glaukos Corporation (GKOS) analysis.
- Corporate Finance Departments: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Financial Advisors: Deliver precise valuation insights to clients interested in Glaukos Corporation (GKOS) stock.
- Students and Instructors: Utilize real-time data to enhance learning and practice in financial modeling.
- Medical Technology Enthusiasts: Gain insights into how companies like Glaukos Corporation (GKOS) are valued in the healthcare market.
What the Glaukos Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Glaukos Corporation (GKOS).
- Real-World Data: Glaukos’ historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis covering profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Interactive charts and tables providing clear, actionable results.